Matrix metalloproteinase-9 (MMP-9) plays a benefi cial role in the sub-acute phase after ischemic stroke. However, unrestrained MMP-9 may disrupt the blood-brain barrier (BBB), which has limited its use for the treatment of brain ischemia. In the present study, we constructed lentivirus mediated hypoxiacontrolled MMP-9 expression and explored its role after stroke. Hypoxia response element (HRE) was used to confine MMP-9 expression only to the hypoxic region of mouse brain after 120-min transient middle cerebral artery occlusion. Lentiviruses were injected into the peri-infarct area on day 7 after transient ischemia. We found hyperexpression of exogenous HRE-MMP-9 under the control of hypoxia, and its expression was mainly located in neurons and astrocytes without aggravation of BBB damage compared to the CMV group. Furthermore, mice in the HRE-MMP-9 group showed the best behavioral recovery compared with the normal saline, GFP, and SB-3CT groups. Therefore, hypoxia-controlled MMP-9 hyperexpression during the sub-acute phase of ischemia may provide a novel promising approach of gene therapy for stroke.
INTRODUCTION
Ischemic stroke is the leading cause of adult disability and the second most common cause of death worldwide [1] .
Over the past two decades, research on brain ischemia has been focused on pathophysiology and therapies including gene therapy, stem cell transplantation, and drug interference [2] [3] [4] . Among them, gene therapy has been the most extensively studied in recent years. Non-viral gene delivery is safer than virus-mediated delivery but is limited by its ineffi ciency [5] . Compared to the adenovirus-associated virus, lentivirus has a large packaging capacity (8 kb) and maintains persistent gene transfer in most tissues [6] , so we used lentivirus-mediated gene therapy.
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases with over 20 members, which can degrade almost all proteinaceous components of the extracellular matrix [7] . MMPs are produced in a latent form and participate in many physiological and pathological processes after activation [8] . MMP-2 (gelatinase A) and MMP-9 ( gelatinase B) are expressed in the brain and can be easily identified by zymography during brain injury and repair [8, 9] . The proteolytic property of MMP-9 may result in tissue damage by attacking the basal lamina and extracellular matrix. Furthermore, as part of the neuroinfl ammatory response, MMP-9 may also lead to vasogenic or cytotoxic edema, hemorrhagic transformation, and neuronal apoptosis [10] . However, recently, MMP-9
has been implicated in tissue repair such as extracellular matrix remodeling, axonal regeneration, remyelination, and the facilitation of neurogenesis and angiogenesis [11] [12] [13] [14] .
These benefi cial roles of MMP-9 may be helpful in treating diseases such as ischemic stroke.
MMP-9 is associated with the progress of stroke and plays opposing roles in the acute and delayed phases of Hongxia Cai, in ischemic stroke 551 ischemic stroke [15] . It is up-regulated in the fi rst 3 days after stroke (acute phase) in mouse brain, contributing to bloodbrain barrier (BBB) permeability and brain infl ammation [15, 16] .
However, MMP-9 is also elevated 7-14 days after ischemic stroke (sub-acute phase), and plays a beneficial role in promoting brain angiogenesis and functional recovery [15, 17] .
Another study reported that MMP-9 plays key roles in the formation of vascular networks after focal cerebral ischemia [18] . These lines of evidence suggest that strategies to modulate MMP-9 expression at different stages are needed to promote post-stroke recovery. We hypothesized that lentivirus-mediated MMP-9 gene therapy may provide a useful approach for stroke treatment in the sub-acute phase, but uncontrolled MMP-9 expression may induce BBB disruption and brain hemorrhage [15, 16, 19] . Therefore, the safe control of exogenous MMP-9 expression is extremely important. Hypoxia response element (HRE), an enhancer of downstream targeted gene expression, is used for gene regulation based on the focal oxygen concentrations [20] [21] [22] .
Hypoxia-inducible factor 1 (HIF-1) is a protein that accumulates in hypoxic/ischemic tissue. By combining HRE with HIF-1, we produced a vector containing nine copies of HRE bound to HIF-1 alpha, which allowed the targeted gene expression controlled by local hypoxia levels [20, 21] .
Indeed, this vector has been successfully used to control VEGF expression in an ischemic heart model [22] . In conclusion, by using the HRE-HIF system to control MMP-9 expression, we investigated, for the first time, the effect of exogenous HRE-MMP-9 on the BBB and neurological behavior in the sub-acute phase of ischemic stroke.
MATERIALS AND METHODS

HRE-SV40-MMP9 Vector Construction
The SK-H9-SV40 pro plasmid backbone was kindly provided by Dr. Hua Su ( University of California San Francisco). After digestion with Hind III and Sma I, nine copies of HRE and the minimum simian virus 40 (SV40) promoter fragment were cut out. In the lentiviral vector pCDH-CMV-MCS-EF1-copGFP (System Biosciences SBI, Mountain View, CA), the cytomegalovirus (CMV) promoter site was replaced by the 9HRE-SV40 fragment, and the mouse proMMP-9 cDNA structure was inserted into the vector, located downstream of the SV40 promoter.
CMV-MMP9 Vector Construction
MMP9 cDNA was inserted downstream of the CMV promoter in the vector pCDH-CMV-MCS-EF1-copGFP without HRE modifi cation. The control was the same vector but without MMP9 insertion.
Lentiviral MMP9 Production, Purifi cation, and Titration
Lentiviral vector was obtained as previously described [23] .
Briefly, gene-carrier plasmid vector was co-transfected with pDelta (helper plasmid) and VSV-G (envelope protein vector) into HEK293T cells. After collecting the supernatant, [24] . Two microliters of lentiviral vector containing 4×10 9 TU/mL particles was injected into the brain at 300 nl/ min. The Hamilton needle was withdrawn from the brain after 5 min.
E xperimental Design
All animal surgery procedures were approved by the Animal Care and Use Committee of Shanghai Jiao Tong University, Shanghai, China. Mice (a total of 90 mice, excluding deaths and failed models) were randomly divided into four groups (n = 14-17 per group): normal saline group (NS); Lenti-HRE-GFP group (GFP), Lenti-HRE-MMP-9-GFP group, and Lenti-HRE-MMP-9-GFP plus SB-3CT
group. The groups of Lenti-CMV-MMP-9 and Lenti-HRE-MMP-9 were used for the BBB assay and were described in the following part. All groups underwent 120-min tMCAO and were given brain injections on day 7 after ischemia.
To block MMP-9, we used 2-
methyl]-thiirane (SB-3CT, Sigma), which specifi cally inhibits MMP-9-driven pathways in vivo [25, 26] . SB-3CT was diluted in 10% dimethylsulfoxide/90% NS, and was injected intraperitoneally at 10 mg/kg per day for 3 consecutive days beginning from days 18 and 32, after ischemia [27, 28] .
Neurobehavioral testing was performed in each group on days 0 (baseline), 7, 14, 21, 28, and 35 after tMCAO.
Mice were sacrificed on days 21 and 35 for zymography assays. BBB damage was assayed in the HRE-MMP9 and CMV-MMP9 groups on day 21. The experimental design is illustrated in Fig. 1 . 
Transient Middle Cerebral Artery Occlusion in Mice
Adult male ICR mice (Sippr-BK, Shanghai, China) weighing 25-30 g were used for tMCAO. Based on previous studies, mice were anesthetized with ketamine (100 mg/kg)/ xylazine (10 mg/kg, Sigma) [29] . A silicone-coated 6-0 suture After adding fresh developing buffer and incubation for 42 h at 37°C, gels were stained with Coomassie blue (0.05%
Coomassie Brilliant Blue, 30% methanol, 10% acetic acid) for 3 h and then de-stained with 30% methanol containing 10% acetic acid for proper color contrast. The fi nal bands were quantified using GelPro-32 densitometer software (Media Cybernetics, Bethesda, MD).
Blood-Brain Barrier Permeability Assay
Two groups were used for BBB damage assay: Lenti-CMV-MMP-9 and Lenti-HRE-MMP-9. The injection site for MMP-9 was the same as for lentivirus injection. Mice were subjected to brain injections on day 7 and sacrifi ced 3 weeks after ischemia. Immunostaining of the tight junction proteins zonula occludens-1 (ZO-1) and occludin was performed and the percentage of the gap length to the whole tight junction length was calculated [4, 30, 31] .
Immunohistochemistry (IHC)
IHC was performed as previously described [32] . Briefl y, after 
Rotarod Test for Neurological Outcomes
An operator blinded to the group assignment obtained and analyzed the rotarod test data. In this test, the mice were required to balance on a rod with a gradually increased rotating speed (40 revolutions/min for 2 min). Mice were trained in this motor skill for 3 consecutive days before tMCAO and then the test was performed on day 0 before tMCAO for baseline and on days 7, 14, 21, 28, and 35 after tMCAO. The time mice stayed on the rod was recorded [32, 33] .
All rotarod data were analyzed from 3 average trials.
Statistical Analysis
Data are presented as mean ± SD. Statistical analyses were performed using GraphPad Prism version 3.05 (GraphPad Software, Inc., La Jolla, CA). U npaired two-tailed Student's t-test (between two groups) and one-way ANOVA followed by Student-Newman-Keuls (among multiple groups)
were used to evaluate statistical signifi cance. P <0.05 was considered statistically signifi cant.
RESULTS
HRE-Controlled MMP-9 Expression Level in the Ischemic Mouse Brain
To take advantage of the beneficial role of MMP-9 in the sub-acute phase of stroke as well as to avoid its deleterious effects including hemorrhage and cell death [10, 34] , we used an HRE-HIF system to control the expression of MMP-9
in the sub-acute phase of stroke ( Fig. 2A) . To measure the MMP-2/9 activities after in vivo transduction, we performed zymography in the NS, Lenti-HRE-GFP, Lenti-HRE-MMP-9 and Lenti-HRE-MMP-9 + SB-3CT groups. At 3 and 5 weeks after tMCAO, MMP-9 activity increased in the Lenti-HRE-MMP-9 group compared to the other 3 groups (Fig. 2Bb) , but MMP-2 activity remained unchanged in all 4 groups (Fig. 2Bc) . In the sham group, no bright bands were found, suggesting no active MMPs in sham-operated mice ( Supplementary Fig. 1A ). These results indicated successful hyperexpression of MMP-9 without affecting endogenous MMP-2 expression after tMCAO.
To further confi rm the dependence of MMP-9 induction on the HRE, we performed another gel zymogram and found that the MMP-9 level induced by the CMV promoter did not differ in the ischemic and normal brain, but was significantly increased when induced by the SV40-HRE promoter in ischemic brain at 5 weeks after tMCAO (Fig.   2C ). Therefore, in brain tissue, the HRE allowed MMP-9 expression to be controlled under ischemic conditions.
Furthermore, we calculated the ratio of GFP expression area to the whole section area (stained by DAPI) using an image montage technique. The GFP fluorescence ratio was greater in the ischemic brain than in the normal brain at each time point (3, 7, 14, and 28 days after lentivirus injection) after SV40-HRE injection. The GFP fl uorescence area was smaller in the SV40-HRE group than in the CMV group, perhaps because the CMV promoter is stronger than SV40 (Fig. 3) . This result suggested that the ischemic environment together with exogenous HRE enhancer regulated and accelerated downstream gene expression, causing the ischemic brain to exhibit more GFP signal than the normal brain.
MMP9-GFP Was Mainly Expressed in Neurons and
Astrocytes in vivo
To clearly observe the cellular morphology of viral infection in vivo, three fields including the corpus callosum and striatum were observed (Fig. 4A) . To identify the lentivirus- 
HRE-MMP-9 Did Not Severely Damage Tight Junctions in the BBB
To determine whether exogenous HRE-MMP-9 affected BBB permeability, we immunostained for the tight-junction proteins ZO-1 and occludin to detect gaps in the Lenti-CMV-MMP-9 and Lenti-HRE-MMP-9 brain 3 weeks after tMCAO. The results showed fewer gaps in the HRE-MMP-9
group than in the CMV-MMP-9 group (Fig. 5) .
HRE-MMP-9 Reduced Brain Atrophy and Improved
Behavioral Recovery
Brain atrophy volume and behavioral outcome deter mination are commonly used to evaluate therapeutic effects in animal models of stroke [35] . In this study, we found that the HRE-MMP-9 group exhibited less brain atrophy than the CMV group at 3 weeks after ischemia (Fig. 6A) . In the rotarod test, the fall latencies were comparable among the 4 groups until 2 weeks after ischemia. However, the time on the rotarod was longer in the MMP-9 group than in the other 3 groups at 3 and 5 weeks after tMCAO (Fig. 6B ). In the sham group, there was no difference among time points (Supplementary Fig. 1B ). These data indicated that HREcontrolled MMP-9 hyperexpression improved behavioral recovery. 
± SD). (C) Zymogram and its quantifi cation showing MMP-9 levels of both vectors in normal and ischemic brains (5 weeks after
tMCAO; n = 3/group; mean ± SD; *P <0.05 and **P <0.01; n.s., no signifi cant difference).
DISCUSSION
Our results provide the first evidence that MMP-9 expression can be controlled by hypoxia using the HRE-HIF system, and that HRE-regulated MMP-9 hyperexpression can improve the outcome of ischemia in the sub-acute phase without aggravating BBB injury.
MMP-9 plays dual roles after ischemia, up-regulation being detrimental in the acute phase but beneficial in the sub-acute phase [15, 36] . On the one hand, MMP-9 can degrade almost all components of ECM, and its abnormal expression may contribute to brain injury and BBB breakdown in the acute phase of cerebral ischemia [15, 16] .
On the other hand, MMP-9 promotes functional recovery in the repair phase after stroke [15] . These consideration prompted us to maximize the beneficial role of MMP-9 while circumventing its disadvantages during stroke therapy. In the brain, to achieve the optimal enzymatic activity, MMP expression and activity are tightly regulated at the transcriptional and post-translational levels [37] . If unrestrained MMP-9 was delivered into the brain, excessive disruption of extracellular matrix and disorganized branching of blood vessels might be induced [38, 39] . It is known that in acute ischemic stroke (the first 3 days), brain tissue suffers a series of detrimental cascades such as energy failure, excitotoxicity, spreading depression, the generation of free radicals, BBB disruption, infl ammation, and neuronal apoptosis, which may last for several days [1] . MMP-9, one of the productions of these reactions, inevitably worsens the neurological deficits.
Hence, in this study, we induced MMP-9 gene expression 7 days after brain ischemia, which means that edema and Therefore, it is important and necessary to control MMP-9 expression when gene transduction is used.
After preliminary tests, nine copies of HRE was the optimal copy number in response to hypoxia [20, 40] . The SV40 promoter is a eukaryotic promoter that is weaker than the CMV promoter [41] . Only when HRE was conjoined with a relatively weak promoter like SV40, was the characteristic of hypoxic regulation revealed. Furthermore, 9HRE-SV40-VEGF has been successfully used in the treatment of cardiac ischemia and attenuates VEGF-induced brain hemorrhage [22] . Therefore, in this study, we selected nine copies of HRE and the SV40 promoter fragment to control MMP-9 expression. Our results showed that MMP-9 was Furthermore, we injected HRE-MMP-9 into the peri-infarct area at 7 days after tMCAO, and found that lentivirus-mediated HRE-MMP-9 was mainly located in neurons and astrocytes, consistent with the fi nding that the MMP-9 expression level increases in the peri-infarct area at 7-14 days after ischemic stroke, and is mainly localized in neurons and astrocytes [15] . It was noteworthy that a few GFP-positive cells were also NG2-positive, meaning that lentivirus infected some oligodendrocyte progenitor cells (they myelinate axons) [42] . Further investigation is needed to determine whether these NG2-positive cells also play roles during the sub-acute phase of ischemia. Meanwhile, other cell types such as pericytes and microglia also deserve investigation.
Since MMP-9 also degrades tight-junction-related proteins, we explored whether HRE-MMP-9 elevation provoked severe protein damage. Two typical tight-junction proteins were selected -ZO-1 and occludin. We found that gap formation was 10% higher in CMV-MMP-9 mice than that in the HRE-MMP-9 group, indicating that after brain injection, the HRE-MMP-9 system did not worsen gap formation. This may be associated with the low-dose and slow-release model of HRE. Since the BBB-related index is closely associated with stroke outcome, further measurements such as functional leakage assays (like Evan's Blue or IgG staining) are needed [31] . Furthermore, we assessed brain atrophy in both groups at 3 weeks after tMCAO, and found that the HRE-MMP-9 group had less brain tissue loss than the CMV-MMP-9 group, suggesting that the HRE system did not aggravate brain atrophy.
Finally, we showed that MMP-9 hyperexpression promoted behavioral recovery. The rotarod test showed that mice stayed on the rod for longer in the sub-acute phase of stroke in the HRE-MMP-9 group compared to the control groups. Other reports also showed that a sustained defi cit in neurobehavioral tests existed for up to 5 weeks in adult ischemic mice [43] . This provides preliminary evidence that HRE-MMP-9 gene therapy is effective in the sub-acute phase of ischemic stroke treatment. However, how MMP-9 affects brain atrophy and behavioral recovery in the subacute phase after stroke needs further investigation. Our results suggest that hypoxia-controlled MMP-9 is a useful approach to enhancing its beneficial role by attenuating BBB damage and reducing brain atrophy during the subacute ph ase of stroke.
Taken together, our findings suggest that, compared with uncontrolled MMP-9 delivery, HRE-controlled delivery of MMP-9 gene in the sub-acute phase after stroke may provide a promising strategy for the treatment of cerebral ischemia.
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